Alfadil Haroon, Mostafa F Mohammed Saleh, Ali Alahmari, Syed Osman, Ahmed Alotaibi, Hazzaa Alzahrani, Mahmoud Aljurf
{"title":"髓系肿瘤中获得性因子XIII缺乏:病例系列和文献回顾。","authors":"Alfadil Haroon, Mostafa F Mohammed Saleh, Ali Alahmari, Syed Osman, Ahmed Alotaibi, Hazzaa Alzahrani, Mahmoud Aljurf","doi":"10.4103/hemoncstem.hemoncstem-D-24-00034","DOIUrl":null,"url":null,"abstract":"<p><p>Acquired factor XIII (FXIII) deficiency is a rare disorder that could be associated with autoimmune and malignant disorders with a high risk of bleeding. In acute leukemias, acquired FXIII deficiency has been reported and replacement of FXIII helped to control significant bleeding. Here, we report four cases of myeloid neoplasms to have acquired FXIII deficiency with interesting concomitant RUNX1 mutation in the molecular background of two patients. Correction of bleeding complications was successful in all patients with FXIII substitution by FXIII concentrate in three patients and cryoprecipitate in one patient. Studying the association of FXIII deficiency with molecular abnormalities in such neoplasms is needed for better understanding and detection of common pathophysiologic pathways. This could help to avoid severe bleeding during diagnostic or therapeutic interventions in patients at risk.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"245-247"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acquired factor XIII deficiency in myeloid neoplasms: case series and review of literature.\",\"authors\":\"Alfadil Haroon, Mostafa F Mohammed Saleh, Ali Alahmari, Syed Osman, Ahmed Alotaibi, Hazzaa Alzahrani, Mahmoud Aljurf\",\"doi\":\"10.4103/hemoncstem.hemoncstem-D-24-00034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Acquired factor XIII (FXIII) deficiency is a rare disorder that could be associated with autoimmune and malignant disorders with a high risk of bleeding. In acute leukemias, acquired FXIII deficiency has been reported and replacement of FXIII helped to control significant bleeding. Here, we report four cases of myeloid neoplasms to have acquired FXIII deficiency with interesting concomitant RUNX1 mutation in the molecular background of two patients. Correction of bleeding complications was successful in all patients with FXIII substitution by FXIII concentrate in three patients and cryoprecipitate in one patient. Studying the association of FXIII deficiency with molecular abnormalities in such neoplasms is needed for better understanding and detection of common pathophysiologic pathways. This could help to avoid severe bleeding during diagnostic or therapeutic interventions in patients at risk.</p>\",\"PeriodicalId\":516321,\"journal\":{\"name\":\"Hematology/oncology and stem cell therapy\",\"volume\":\"17 4\",\"pages\":\"245-247\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology/oncology and stem cell therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/hemoncstem.hemoncstem-D-24-00034\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/oncology and stem cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/hemoncstem.hemoncstem-D-24-00034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Acquired factor XIII deficiency in myeloid neoplasms: case series and review of literature.
Acquired factor XIII (FXIII) deficiency is a rare disorder that could be associated with autoimmune and malignant disorders with a high risk of bleeding. In acute leukemias, acquired FXIII deficiency has been reported and replacement of FXIII helped to control significant bleeding. Here, we report four cases of myeloid neoplasms to have acquired FXIII deficiency with interesting concomitant RUNX1 mutation in the molecular background of two patients. Correction of bleeding complications was successful in all patients with FXIII substitution by FXIII concentrate in three patients and cryoprecipitate in one patient. Studying the association of FXIII deficiency with molecular abnormalities in such neoplasms is needed for better understanding and detection of common pathophysiologic pathways. This could help to avoid severe bleeding during diagnostic or therapeutic interventions in patients at risk.